| Company | Date | Position | Consensus β | Price Target β | 2-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
ATEC
Alphatec Holdings
|
Oct 30, 2026 | BUY |
Strong Buy
+117.0% avg upside
23 analysts
|
$11.00
56.25% Upside
|
-1.4% | Β· |
|
BLCO
Bausch + Lomb Corporation
|
Oct 29, 2026 | HOLD |
Buy
+7.6% avg upside
20 analysts
|
$19.00
4.91% Downside
|
+2.1% | Β· |
|
GKOS
Glaukos
|
Oct 29, 2026 | BUY |
Strong Buy
-18.6% avg upside
21 analysts
|
$225.00
5.31% Downside
|
+0.3% | Β· |
|
CLPT
ClearPoint Neuro
|
Oct 29, 2026 | BUY |
Strong Buy
+99.9% avg upside
7 analysts
|
$18.00
68.67% Upside
|
-26.5% | Β· |
|
SGP
SpyGlass Pharma
|
Oct 26, 2026 | BUY |
Strong Buy
+36.5% avg upside
6 analysts
|
$42.00
30.30% Upside
|
-0.8% | Β· |
|
TMDX
TransMedics Group
|
Oct 15, 2026 | HOLD |
Strong Buy
+44.6% avg upside
15 analysts
|
$65.00
1.56% Downside
|
+22.7% | Β· |
|
GMED
Globus Medical
|
Oct 07, 2026 | HOLD |
Strong Buy
+18.9% avg upside
24 analysts
|
$85.00
8.90% Upside
|
-3.6% | Β· |
|
CH:ALC
Alcon
|
Oct 06, 2026 | HOLD |
Strong Buy
+19.4% avg upside
36 analysts
|
$57.45
2.86% Downside
|
+16.4% | Β· |
|
STAA
Staar Surgical
|
Sep 29, 2026 | BUY |
Buy
+42.3% avg upside
16 analysts
|
$31.00
26.40% Upside
|
+16.0% | Β· |
|
RXST
RxSight
|
Aug 10, 2026 | HOLD |
Hold
+86.0% avg upside
13 analysts
|
$7.00
43.70% Upside
|
-26.5% | Β· |
|
SGHT
Sight Sciences
|
Aug 06, 2026 | BUY |
Buy
+9.8% avg upside
14 analysts
|
$8.00
14.19% Downside
|
+47.9% | Β· |
|
OFIX
Orthofix Medical
|
Aug 05, 2026 | BUY |
Buy
+203.8% avg upside
15 analysts
|
$13.00
43.30% Upside
|
-36.0% | Β· |
|
IRIX
Iridex
|
May 15, 2024 | HOLD |
Strong Buy
+543.7% avg upside
3 analysts
|
$2.00
180.88% Upside
|
-61.9% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.